Two British doctors recently wrote a piece in the BBC urging the U.K. National Health Service (NHS) to switch from Merck’s Cervarix human papillomavirus (HPV) vaccine to GlaxoSmithKline’s (GSK) Gardasil HPV vaccine, in its mass vaccination program for young girls. And the two “experts” admit that they only say publicly what helps the vaccine to be well received by the public.
“We, as consultants in sexual health, have been told to say nothing publicly that would damage the current (HPV) vaccine campaign,” they state in their piece.
Drs. Colm O’Mahony and Steve Taylor insist that because Gardasil allegedly protects against genital warts as well as HPV, it is superior to Cervarix, which NHS currently administers to young girls. As long as Gardasil is the same price or cheaper than Cervarix, then NHS should use it, wrote the doctors. And if it is more expensive, then Cervarix is the next best option, they say.
But what is missing from their recommendations is the fact that Dr. O’Mahony has been on the advisory boards of both GSK and Merck, and has received “lecture fees” for his services. This clear conflict of interest may be the precise reason why no mention is made in the BBC piece about the countless thousands of young girls that have become debilitated or died from both Cervarix and Gardasil.